• 1
    Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T. et al.,Differential tumor surveillance by natural killer and NKT cells. J. Exp. Med. 2000. 191: 661668.
  • 2
    Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L. and Yokoyama, W. M., In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 2000. 97: 27312736.
  • 3
    Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000. 356: 17951799.
  • 4
    Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M. et al., NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 2009. 119: 12511263.
  • 5
    Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S. et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002. 295: 20973000.
  • 6
    Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C. and Moretta, A., Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011. 117: 764771.
  • 7
    Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S., Functions of natural killer cells. Nat. Immunol. 2008. 9: 503510.
  • 8
    Moretta, A., Marcenaro, E., Sivori, S., Della Chiesa, M., Vitale, M. and Moretta, L., Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 2005. 26: 668675.
  • 9
    Caligiuri, M. A., Human natural killer cells. Blood 2008. 112: 461469.
  • 10
    Bellora, F., Castriconi, R., Dondero, A., Reggiardo, G., Moretta, L., Mantovani, A., Moretta, al., The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc. Natl. Acad. Sci. USA 2010. 107: 2165921664.
  • 11
    Bottino, C., Moretta, L., Pende, D., Vitale, M. and Moretta, A., Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol. Immunol. 2004. 41: 569575.
  • 12
    Lanier, L. L., NK cell recognition. Annu. Rev. Immunol. 2005. 23: 225274.
  • 13
    Bryceson, Y. T., March, M. E., Ljunggren, H. G. and Long, E. O., Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006. 107: 159166.
  • 14
    Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. al., Innate or adaptive Immunity? The example of natural killer cells. Science 2011. 331: 4449.
  • 15
    Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727729.
  • 16
    Cosman, D., Mülberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M. and Chalupny, N. J., ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001. 14: 123133.
  • 17
    Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C. et al., Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 2003. 198: 557567.
  • 18
    Fuchs, A. and Colonna, M., The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin. Cancer. Biol. 2006. 16: 359366.
  • 19
    Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A. et al., Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007. 27: 965974.
  • 20
    Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B. et al., The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 2009. 206: 14951503.
  • 21
    Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R. et al., NKp44, a novel triggering surface molecule specifically expressed by activated Natural Killer cells is involved in non-MHCrestricted tumor cell lysis. J. Exp. Med. 1998. 187: 20652072.
  • 22
    Halfteck, G. G., Elboim, M., Gur, C., Achdout, H., Ghadially, H. and Mandelboim, O., Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 2009. 182: 22212230.
  • 23
    Castriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F. et al., Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl. Acad. Sci. USA 2004. 101: 1264012645.
  • 24
    Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003. 3: 133146.
  • 25
    Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Bougras, G. et al., Distinct roles of IL-12 and IL-15 in human Natural Killer cell activation by DC from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 2004. 101: 1660616611.
  • 26
    Overwijk, W. W. and Schluns, K. S., Functions of gammaCcytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 2009. 132: 153165.
  • 27
    Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J. et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000. 408: 5763.
  • 28
    Mailliard, R. B., Alber, S. M., Shen, H., Watkins, S. C., Kirkwood, J. M., Herberman, R. B. and Kalinski, P., IL-18-induced CD83+CCR7+NK helper cells. J. Exp. Med. 2005. 202: 941953.
  • 29
    Marcenaro, E., Della Chiesa, M., Bellora, F., Parolini, S., Millo, R., Moretta, L. and Moretta, A., IL-12 or IL-4 prime humanNKcells to mediate functionally divergent interactions with dendritic cells or tumors. J. Immunol. 2005. 17: 39923998.
  • 30
    Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R. et al., Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 2003. 100: 41204125.
  • 31
    Della Chiesa, M., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L. et al., The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006. 108: 41184125.
  • 32
    Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P. et al., Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 2009. 106: 2084720852.
  • 33
    Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., Kubin, M. et al., Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002. 62: 61786186.
  • 34
    Pietra, G., Manzini, C., Vitale, M., Balsamo, M., Ognio, E., Boitano, M., Queirolo, P. et al., Natural Killer cells kill human melanoma cells with phenotypic characteristics of cancer stem cells. Int. Immunol. 2009. 21: 793801.
  • 35
    Wang, Z., Hu, X. Z., Tatake, R. J., Yang, S. Y., Zeff, R. A. and Ferrone, S., Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cells. Cancer Res. 1993. 53: 43034309.
  • 36
    Della Chiesa, M., Falco, M., Parolini, S., Bellora, F., Petretto, A., Romeo, E., Balsamo, M. et al., GPR56 as a novel marker identifying the CD56dullCD16+NK cell subset both in blood stream and inflamed peripheral tissues. Int. Immunol. 2010. 22: 91100.
  • 37
    Xu, L., Begum, S., Hearn, J. D. and Hynes, R. O., GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis Proc. Natl. Acad. Sci. USA 2006. 103: 90239028.
  • 38
    Carosella, E. D., Favier, B., Rouas-Freiss, N., Moreau, P. and Lemaoult, J., Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008. 111: 48624870.
  • 39
    Marín, R., Riuz-Cabello, F., Pedrinaci, S., Mendez, R., Jimenez, P., Geraghty, D. E. and Garrido, F., Analysis of HLA-E expression in human tumors. Immunogenetics 2003. 54: 767775.
  • 40
    López-Botet, M., Llano, M., Navarro, F. and Bellón, T., NK cell recognition of non-classical HLA class I molecules. Semin. Immunol. 2000. 12: 109119.
  • 41
    Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P. et al., Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011. 71: 54125422.
  • 42
    Malmberg, K. J., Levitsky, V., Norell, H., Teixeira de Matos, C., Carlsten, M., Schedvins, K., Rabbani, H. et al., IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 2002. 110: 15151523.
  • 43
    Rebmann, V., Wagner, S. and Grosse-Wilde, H., HLA-G expression in malignant melanoma. Semin. Cancer. Biol. 2007. 17: 422429.
  • 44
    Lin, A., Zhu, C. C., Chen, H. X., Chen, B. F., Zhang, X., Zhang, J. G., Wang, Q. et al., Clinical relevance and functional implications for human leucocyte antigen-G expression in non-small-cell lung cancer. J. Cell. Mol. Med. 2010. 14: 23182329.
  • 45
    de Kruijf E. M., Sajet, A., van Nes, J. G. H., Natanov, R., Putter, H., Smit, V. T., Liefers, G. J. et al., HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 2010. 185: 74527459.
  • 46
    Groh, V., Wu, J., Yee, C. and Spies, T., Tumor-derived solubile MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002. 419: 734738.
  • 47
    Schwinn, N., Vokhminova, D., Sucker, A., Textor, S., Striegel, S., Moll, I., Nausch, N. et al., Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int. J. Cancer 2009. 124: 15941504.
  • 48
    Lee, J. H., Park, S., Cheon, S., Lee, J. H., Kim, S., Hur, D. Y., Kim, T. S. et al., 1,25-Dihydroxyvitamin D₃enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur. J. Immunol. 2011. 41:29372946.
  • 49
    Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. and Zitvogel, L., Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 2008. 9: 486494.
  • 50
    Mortier, E., Woo, T., Advincula, R., Gozalo, S. and Ma, A., IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 2008. 205: 12131225.
  • 51
    Chang, C. M., Lo, C. H., Shih, Y. M., Chen, Y., Wu, P. Y., Tsuneyama, K., Roffler, S. R. et al., Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum. Gene Ther. 2010. 21: 611621.